AGNP 2026 Update Overhauls Therapeutic Drug Monitoring in Neuropsychopharmacology

The AGNP TDM task force delivers a systematically revised, evidence-based set of therapeutic and dose-related reference ranges for 160 neuropsychiatric drugs, plus integrated pharmacogenetic guidance, giving TDM pharmacists new interpretive tools and expanded drug coverage.

AGNP Consensus Guidelines TDM Update 2026Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrietherapeutic drug monitoringneuropsychopharmacologyantidepressantsantipsychoticsmood stabilizersantiseizure medicationsopioid agonistspharmacogeneticsCYP450 Pharmacokinetics / TDM

Background Information

Updated TDM guidelines refine neuropsychiatric drug dosing strategies.

The guidelines update therapeutic drug monitoring (TDM) practices in neuropsychopharmacology, enhancing precision in drug therapy. Therapeutic reference ranges updated for 160 drugs, with 15 requiring obligatory TDM. This comprehensive update aids in personalized treatment, providing clear guidance on when TDM should be applied, but focuses on neuropsychiatric drugs. Updated TDM guidelines offer precise dosing strategies for improved neuropsychiatric treatment outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Hart XM, Gründer G, Hiemke C, Adamovic I, Amann F, Baumann P, Bergemann N, Brandt C, Clement HW, Conca A, Deckert J, Dietmaier O, Eckermann G, Egberts K, Endres K, Erlacher N, Fekete S, Ferrea S, Florio V, Gerlach M, Haen E, Hahn M, Havemann-Reinecke U, Hefner G, Jost WH, Kuzin M, Laux G, Leucht S, Maniscalco I, Menke A, Messer T, Moessner R, Müller DJ, Müller T, Paulzen M, Petri H, Pfeifer P, Pfuhlmann B, Riederer P, Roll SC, Scherf-Clavel M, Schwarz M, Steimer W, Stingl JC, Toto S, Ulrich S, Zernig G, Zurek G, Unterecker S, Schoretsanitis G

Citation: Hart XM, Gründer G, Hiemke C, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry. 2026;59(4):166-295. doi:10.1055/a-2860-7861

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →